Genetics

CRISPR-Cas9 gene editing shows very low risk of mistakes

Along with the promise that CRISPR-Cas9 gene editing technology can offer new human therapies is the need to ensure its safety. A recent study showed that CRISPR-Cas9 did not produce off-target gene mutations in zebrafish. ...

Medical economics

German vaccine maker CureVac surges almost 250% in Nasdaq debut

Shares of German biotech company CureVac, which is developing a leading coronavirus vaccine candidate, rocketed Friday in its first day of trading in New York after raising more than $200 million in an initial public offering.

Diseases, Conditions, Syndromes

What you need to know about Nipah virus

A mysterious illness causing fevers and headaches and leading to rapid development of acute encephalitis (within a couple of weeks of symptom onset), caused an outbreak of nearly 300 reported cases and over 100 fatalities ...

page 1 from 3